Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although statin therapy reduces cardiovascular risk, its relationship with the development of diabetes is controversial. The first study (West of Scotland Coronary Prevention Study [WOSCOPS]) that evaluated this association reported a small protective effect but used nonstandardized criteria for diabetes diagnosis. However, results from subsequent hypothesis-testing trials have been inconsistent. The aim of this meta-analysis is to evaluate the possible effect of statin therapy on incident diabetes. RESEARCH DESIGN AND METHODS: A systematic literature search for randomized statin trials that reported data on diabetes through February 2009 was conducted using specific search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothesis-testing data were available from the Heart Protection Study (HPS), the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9 years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores were assessed with the Q and I2 statistic. RESULTS: In the meta-analysis of the hypothesis-testing trials, we observed a small increase in diabetes risk (RR 1.13 [95% CI 1.03–1.23]) with no evidence of heterogeneity across trials. However, this estimate was attenuated and no longer significant when the hypothesis-generating trial WOSCOPS was included (1.06 [0.93–1.25]) and also resulted in significant heterogeneity (Q 11.8 [5 d.f.], P = 0.03, I2 = 57.7%). CONCLUSIONS: Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship of statin therapy to incident diabetes remains uncertain. Future statin trials should be designed to formally address this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (162,163), which may be limited to those with diabetes risk factors.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (156,157), which may be limited to those with diabetes risk factors and/or impaired glucose tolerance.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In primary prevention, however, among individuals with no previous cardiovascular events, its net benefit is more controversial (156,168).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“In primary prevention, however, among patients with no previous cardiovascular events, its net bene fi t is more controversial (129,140).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [129]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“To assess heterogeneity across studies, we used the Cochran Q statistic based on the pooled RR by Mantel-Haenszel and measured inconsistency (I(2); the percentage of total variance across studies attributable to heterogeneity rather than chance) of treatment effects across trials (9).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The summary RR and its 95% CI were estimated using the DerSimonian and Laird method for random effects (8).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Subsequent statin trials did not confirm this protective effect, and in the recent JUPITER a small but significant increase in physician-reported diabetes was reported among statin users compared with those taking placebo, although in the absence of any effect on glucose levels (6).”
ResultSelf-citationSever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 1×
“A few studies have suggested that statin use may result in an increase in A1C levels (2,17), although these effects have been quite small.”
BackgroundRosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844 · cited 1×
“(1) reported an inverse association between pravastatin use and diabetes incidence in the WOSCOPS (RR 0.”
Background
Research works printed but not linked: 1
- Sabatine, 2004, High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract), Circulation, 110, S834
Cited by
Items 101–200 of 439
Evans, M., Rumberger, J. A., Azumano, I., Napolitano, J. J., Citrolo, D., & Kamiya, T. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s57116 · Cited by 65
Zhao, Z., Du, S., Shen, S., Luo, P., Ding, S., Wang, G., & Wang, L. (2019) · Medicine · doi:10.1097/md.0000000000014400 · Cited by 54
Statin therapy: does sex matter?
Faubion, S. S., Kapoor, E., Moyer, A. M., Hodis, H. N., & Miller, V. M. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001412 · Cited by 61
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1988568 · Cited by 54
de Lorgeril, M., Salen, P., Defaye, P., & Rabaeus, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-5 · Cited by 55
“Data extracted from commercial RCTs and post-hoc analyses, including meta-analyses of selected RCTs [76-78], do not help to clarify the issue.”
InfluentialDifferential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients
Koh, K. K., Quon, M. J., Sakuma, I., Han, S. H., Choi, H., Lee, K., & Shin, E. K. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.028 · Cited by 55
Pharmacological and non-pharmacological interventions to influence adipose tissue function
Westerink, J., & Visseren, F. L. J. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-13 · Cited by 60
“without clear heterogeneity between statins [142,143].”
Stigmasterol prevents glucolipotoxicity induced defects in glucose-stimulated insulin secretion
Ward, M., Li, G., Barbosa-Lorenzi, V. C., & Hao, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10209-0 · Cited by 59
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 55
A Trial-Based Approach to Statin Guidelines
Ridker, P. M., & Wilson, P. W. F. (2013) · JAMA · doi:10.1001/jama.2013.276529 · Cited by 52
Self-citationZafrir, B., & Jain, M. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6534-9 · Cited by 56
“The authors concluded that the relationship of statin therapy to incident diabetes remained uncertain [8].”
BackgroundStatin therapy and related risk of new-onset type 2 diabetes mellitus
Ruscica, M., Macchi, C., Morlotti, B., Sirtori, C. R., & Magni, P. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.003 · Cited by 56
TAZ couples Hippo/Wnt signalling and insulin sensitivity through Irs1 expression
Hwang, J.-H., Kim, A. R., Kim, K. M., Park, J. I., Oh, H. T., Moon, S. A., Byun, M. R., Jeong, H., Kim, H. K., Yaffe, M. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08287-x · Cited by 58
Ling, Z., Shu, N., Xu, P., Wang, F., Zhong, Z., Sun, B., Li, F., Zhang, M., Zhao, K., Tang, X., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.023 · Cited by 52
New onset diabetes mellitus induced by statins: current evidence
Chrysant, S. G. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1292107 · Cited by 55
Rasmussen, L. D., Kronborg, G., Larsen, C. S., Pedersen, C., Gerstoft, J., & Obel, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052828 · Cited by 51
“The clinical importance of this potential risk seems to be outweighed by the cardiovascular benefit in individuals for whom statin therapy is recommended, [43–45].”
BackgroundBiomarkers and immune-modulating therapies for Type 2 diabetes
Brooks‐Worrell, B., Narla, R. R., & Palmer, J. P. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.002 · Cited by 50
Gagne, J. J., Glynn, R. J., Rassen, J. A., Walker, A. M., Daniel, G. W., Sridhar, G., & Schneeweiß, S. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.369 · Cited by 47
“Another metaanalysis reported similar findings and that any effect of statins on diabetes is likely a class effect (17).”
ResultStatin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis
Cui, J. Y., Zhou, R., Han, S., Wang, T., Wang, L., & Xie, X. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12690 · Cited by 55
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L., Fogacci, F., & Cicero, A. F. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 47
“Furthermore, large meta-analyses showed that statin use is associated with 9–13% increase in diabetes risk [11,12].”
BackgroundMonitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
“Recent meta-analyses have shown an increased risk of developing diabetes during statin treatment [75, 76].”
BackgroundThe role of soluble fiber intake in patients under highly effective lipid-lowering therapy
Ramos, S. C., Fonseca, F. A., Kasmas, S. H., Moreira, F. T., Helfenstein, T., Borges, N. C., Moreno, R. A., Rezende, V. M., Silva, F. C., & Izar, M. C. (2011) · Nutrition Journal · doi:10.1186/1475-2891-10-80 · Cited by 45
“Recently, two meta-analyses have shown a slight increase in the rates of new-onset diabetes mellitus in patients treated with statins [34,35].”
BackgroundHodis, H. N., & Mack, W. J. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12281 · Cited by 47
“23), accounting for eight additional cases of new-onset diabetes mellitus per 10,000 individuals per year of statin therapy.(29) In another meta-analysis of 13 RCTs of 91,140 women and men, statin therapy was associated with a significantly greater risk of incident diabetes mellitus than placebo (HR = 1.”
BackgroundChapman, M. J., Orsoni, A., Robillard, P., Hounslow, N., Sponseller, C. A., & Giral, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.874989 · Cited by 44
Effects of Simvastatin on Glucose Metabolism in Mouse MIN6 Cells
Zhou, J., Li, W., Xie, Q., Hou, Y., Zhan, S., Yang, X., Xu, X., Cai, J., & Huang, Z. (2014) · Journal of Diabetes Research · doi:10.1155/2014/376570 · Cited by 52
Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy
Erlandson, K. M., Jiang, Y., Debanne, S. M., & McComsey, G. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ554 · Cited by 43
“increased risk for diabetes with statin use [11] prompted a 2012”
BackgroundSkoumas, J., Liontou, C., Chrysohoou, C. A., Masoura, C., Aznaouridis, K. A., Pitsavos, C., & Stefanadis, C. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.08.047 · Cited by 41
Teramoto, T., Shirai, K., Daida, H., & Yamada, N. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-29 · Cited by 43
“Further, recent reports indicate that statin therapy is associated with a slightly higher risk of developing diabetes [35,36].”
The mevalonate coordinates energy input and cell proliferation
Gong, L., Xiao, Y., Xia, F., Wu, P., Zhao, T., Xie, S., Wang, R., Wen, Q., Zhou, W., Xu, H., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1544-y · Cited by 48
Iqbal, M. Z., Khan, A. H., Iqbal, M., & Sulaiman, S. A. S. (2019) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_138_19 · Cited by 52
“[7] [14-16] These reviews focused on many types of pharmacist interventions including self-care-related interventions, adherence, and compliance or on counseling but always resulted in a significant effect on the outcomes of diabetes mellitus.”
Statins and New-Onset Diabetes: A Retrospective Longitudinal Cohort Study
Ma, T., Tien, L., Fang, C.-L., Liou, Y., & Jong, G. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.08.004 · Cited by 45
Goldstein, M. R., & Mascitelli, L. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0368-x · Cited by 42
“Recent meta-analyses of clinical trials support the notion that statin therapy modestly and significantly increases the risk of new-onset diabetes by roughly 10 % [20, 27], which corresponds to an absolute value of 1 additional case of diabetes for every 1,000 patients treated with statins for a year [20].”
BackgroundLiew, S. M., Lee, P. Y., Hanafi, N. S., Ng, C. J., Wong, S. S. L., Chia, Y. C., Lai, P. S. M., Zaidi, N. F. M., & Khoo, E. M. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-53 · Cited by 41
“from two trials [2,3] as well as meta-analysis and cohort studies [4-6].”
MethodStatins and the potential for higher diabetes mellitus risk
Yandrapalli, S., Malik, A. H., Guber, K., Rochlani, Y. M., Pemmasani, G., Jasti, M., & Aronow, W. S. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1659133 · Cited by 46
Nakagomi, A., Shibui, T., Kohashi, K., Kosugi, M., Kusama, Y., Atarashi, H., & Shimizu, W. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.29520 · Cited by 44
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 43
“Statins, and in particular high-dose statins, have been associated with an increased risk of impaired glucose tolerance and type 2 diabetes [14, 15].”
BackgroundMorbidity risks among older adults with pre-existing age-related diseases
Akushevich, I. V., Kravchenko, J. S., Ukraintseva, S. V., Arbeev, K. G., Kulminski, A. M., & Yashin, A. I. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.09.005 · Cited by 44
“However, some of the widely used medicine such as antidepressants and statins may result in increased risk of diabetes (Rajpathak et al., 2009; Rubin et al., 2008).”
BackgroundEmerging Roles of Small GTPases in Islet β-Cell Function
Veluthakal, R., & Thurmond, D. C. (2021) · Cells · doi:10.3390/cells10061503 · Cited by 47
Rahman Chowdhury, S. (2021) · Journal of Endocrinology and Thyroid Research · doi:10.19080/jetr.2021.05.555674 · Cited by 40
Jones, P. H., Cusi, K. J., Davidson, M. H., Kelly, M. T., Setze, C. M., Thakker, K. M., Sleep, D. J., & Stolzenbach, J. C. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/10061630-000000000-00000 · Cited by 47
Yokote, K., Shimano, H., Urashima, M., & Teramoto, T. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.47 · Cited by 45
Statins exhibit anticancer effects through modifications of the pAkt signaling pathway
Stenius, U. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1223 · Cited by 46
Ko, D. T., Wijeysundera, H. C., Jackevicius, C. A., Yousef, A., Wang, J., & Tu, J. V. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000015 · Cited by 43
Statin therapy with or without ezetimibe and the progression to diabetes
Barkas, F., Elisaf, M., Liberopoulos, E. N., Klouras, E., Liamis, G. L., & Rizos, E. C. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.015 · Cited by 40
Tsunoda, T., Nozue, T., Yamada, M., Mizuguchi, I., Sasaki, M., & Michishita, I. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.12.026 · Cited by 39
Statins and the brain: New perspective for old drugs
Ling, Q., & Tejada-Simon, M. V. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.013 · Cited by 43
Associations of statin use with glycaemic traits and incident type 2 diabetes
Ahmadizar, F., Ochoa‐Rosales, C., Glisic, M., Franco, O. H., Muka, T., & Stricker, B. H. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13898 · Cited by 38
“The literature so far on statin use and the risk of developing type 2 diabetes has been limited by several drawbacks: (i) underestimated cases of incident type 2 diabetes due to the inclusion of questionnaire‐based data, (ii) short follow‐up time not adequately taking into account the long‐term effects of statins, and…”
BackgroundStatin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature
Colbert, J. D., & Stone, J. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.021 · Cited by 39
“Similarly, in 2009, Rajpathak and colleagues performed a meta-analysis of incident diabetes in 6 major statin trials (WOSCOPS, HPS, ASCOT, LIPID, CORONA, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin [JUPITER]).(8) They did find a small increase in the risk of develo…”
Chen, W., Sheu, W. H., Tseng, P., Lee, T., Lee, W., Chang, P., & Chiang, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154672 · Cited by 41
The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations
Agarwala, A., Kulkarni, S., & Maddox, T. M. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0995-6 · Cited by 42
Ganesan, S., & Ito, M. K. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0177 · Cited by 44
Statins and their increased risk of inducing diabetes
Agouridis, A. P., Kostapanos, M. S., & Elisaf, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1096343 · Cited by 39
“38) compared with 28,751 receiving placebo [33].”
Chan, D. C., Pang, J., & Watts, G. F. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0472-7 · Cited by 40
Role for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 41
Therapies for diabetic dyslipidaemia
Bell, D. S. H., Badarin, F. J. A., & O’Keefe, J. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01342.x · Cited by 39
South African Dyslipidaemia Guideline Consensus Statement
Klug, E. Q. (2012) · South African Medical Journal · doi:10.7196/samj.5502 · Cited by 48
Orho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 35
Risk of new-onset diabetes associated with statin use
Beckett, R. D., Schepers, S. M., & Gordon, S. K. (2015) · SAGE Open Medicine · doi:10.1177/2050312115605518 · Cited by 35
Shen, L., Gu, Y., Qiu, Y., Cheng, T., Nie, A., Cui, C., Fu, C., Li, T., Li, X., Fu, L., et al. (2019) · Diabetes · doi:10.2337/db19-0178 · Cited by 37
Secondary hypertriglyceridemia in children and adolescents
Blackett, P. R., Wilson, D. P., & McNeal, C. J. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.006 · Cited by 41
Lu, Y., Cheng, Z., Zhao, Y., Chang, X., Chan, C., Bai, Y., & Cheng, N. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.025 · Cited by 44
Statins and diabetes risk: Fact, fiction, and clinical implications
Rocco, M. B. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12091 · Cited by 38
Low density lipoprotein mimics insulin action on autophagy and glucose uptake in endothelial cells
Zhu, L., Wu, G., Yang, X., Jia, X., Li, J., Bai, X., Li, W., Zhao, Y., Li, Y., Cheng, W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39559-7 · Cited by 33
Statin use and risk of diabetes mellitus in postmenopausal women
Katsiki, N., & Banach, M. (2012) · Clinical Lipidology · doi:10.2217/clp.12.28 · Cited by 32
Impact of Statin Use on Development of New-Onset Diabetes Mellitus in Asian Population
Rha, S., Choi, B. G., Seo, H. S., Park, S., Park, J. Y., Chen, K., Park, Y., Choi, J. Y., Shim, M.-S., Kim, J. B., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.11.009 · Cited by 37
Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial
Braun, L. R., Feldpausch, M. N., Czerwonka, N., Weiss, J. J., Branch, K. L., Lee, H., Martínez-Salazar, E. L., Torriani, M., Sponseller, C. A., Grinspoon, S. K., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01446 · Cited by 32
Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature
Bell, D. S. H., DiNicolantonio, J. J., & O’Keefe, J. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12254 · Cited by 32
“The hydrophilic statin rosuvastatin not only showed a 26% increased incidence of new onset diabetes in the JUPITER study but also in two meta-analyses of rosuvastatin therapy the incidence of diabetes was increased by 28 and 18% [7,19,20].”
BackgroundA Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 34
“Diabetes mellitus is the most debated endocrine adverse effect of statin therapy [106–108].”
BackgroundNavarese, E. P., Szczesniak, A. M., Kołodziejczak, M. M., Górny, B., Kubica, J., & Suryapranata, H. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0053-0 · Cited by 38
“[16] performed a meta-analysis of five trials involving 51,619 participants, among whom 1,943 developed DM.”
MethodChung, C., Lin, M., Chang, C., Cheng, H.-W., Chang, S., Wang, P., Chang, H., & Lin, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.018 · Cited by 31
Lee, J., Noh, Y., Shin, S., Lim, H., Park, R. W., Bae, S. K., Oh, E., Kim, G. J., Kim, J. H., & Lee, S. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117150 · Cited by 37
“Subsequent meta-analyses confirmed the observed effect.(20,21) Rajpathak et al examined the effect of statins on T2DM risk by conducting a meta-analysis on six primary and secondary prevention trials, totaling 57,593 patients.”
Birnbaum, Y., Nanhwan, M. K., Ling, S., Perez-Polo, J. R., Ye, Y., & Bajaj, M. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6546-5 · Cited by 32
for the J-PREDICT study investigators, Yamazaki, T., Kishimoto, J., Ito, C., Noda, M., Odawara, M., Terauchi, Y., Shiba, T., Kitazato, H., Iwamoto, Y., et al. (2011) · Diabetology International · doi:10.1007/s13340-011-0032-0 · Cited by 36
Yeboah, J., Sillau, S., Delaney, J. A., Blaha, M. J., Michos, E. D., Young, R. L., Qureshi, W., McClelland, R. L., Burke, G. L., Psaty, B. M., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2014.12.018 · Cited by 32
Statins and New-Onset Diabetes
Barylski, M., Nikolić, D., Banach, M., Toth, P. P., Montalto, G., & Rizzo, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660678 · Cited by 30
“On the other hand, several studies showed that frequently used statins (simvastatin, atorvastatin and rosuvastatin) - have negative effects on glycemic control [4-6,13,24,26,29-32] as well on insulin action and glucose uptake [33-35].”
BackgroundMethodInfluentialStatin-Associated Diabetes Mellitus: Review and Clinical Guide
Backes, J. M., Kostoff, M. D., Gibson, C., & Ruisinger, J. F. (2016) · Southern Medical Journal · doi:10.14423/smj.0000000000000423 · Cited by 33
“23).(18) In 2010, a meta-analysis of 13 placebo or standard care RCT statin trials was performed.”
BackgroundZhu, J., Han, J., Liu, L., Liu, Y., Xu, W., Li, X., Yang, L., Gu, Y., Tang, W., Shi, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110568 · Cited by 34
Hafner, M., Juvan, P., Režen, T., Monostory, K., Pascussi, J., & Rozman, D. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834a5585 · Cited by 36
Castro, M. R., Simon, G., Cha, S. S., Yawn, B. P., Melton, L. J., & Caraballo, P. J. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-015-3583-0 · Cited by 34
Pérez‐Calahorra, S., Civeira, F., Guallar‐Castillón, P., Pintó, X., Banegas, J. R., Pedro‐Botet, J., Tembra, M. S., Mauri, M., Soler, C., Rodríguez‐Artalejo, F., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319896138 · Cited by 29
Drug safety evaluation of rosuvastatin
Toth, P. P., & Dayspring, T. D. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.626764 · Cited by 32
Kajinami, K., & Yasusyuki, K. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s13492 · Cited by 31
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 36
The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function
Cheng, T., Li, C., Shen, L., Wang, S., Li, X., Fu, C., Li, T., Liu, B., Gu, Y., Wang, W., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.797062 · Cited by 35
The JUPITER Trial: Responding to the Critics
Ridker, P. M., & Glynn, R. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.08.025 · Cited by 33
Self-citationAbbas, A., Milles, J. J., & Ramachandran, S. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7591 · Cited by 34
Statins exacerbate glucose intolerance and hyperglycemia in a high sucrose fed rodent model
Seshadri, S., Naimisha, R., Prajapati, B., Mandaliya, D. K., Patel, S. J., Muggalla, C. S., Kapadia, B. B., Babu, P. P., Misra, P., & Saxena, U. (2019) · Scientific Reports · doi:10.1038/s41598-019-45369-8 · Cited by 34
Statin-Associated Incident Diabetes: A Literature Review
Park, Z. H., Juska, A., Dyakov, D., & Patel, R. V. (2014) · The Consultant Pharmacist · doi:10.4140/tcp.n.2014.317 · Cited by 33
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
Kosmas, C. E., Silverio, D., Sourlas, A., Garcia, F., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212562 · Cited by 36
Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults
Bhattacharya, R., Ajmera, M., Bhattacharjee, S., & Sambamoorthi, U. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.016 · Cited by 28
Lipworth, L., Fazio, S., Kabagambe, E., Munro, H., Nwazue, V., Tarone, R., McLaughlin, J., Blot, W., & Sampson, U. (2013) · Clinical Epidemiology · doi:10.2147/clep.s53492 · Cited by 26
“Table 1 self-reported high cholesterol and statin or other lipid-lowering medication use according to baseline characteristics of 67,385 sCCs participants, 2002–2009 Characteristic High cholesterol n=20,722 (31%) No high cholesterol n=46,663 (69%) n (%) Statinsb n=10,045 (15%) n (%) Other drugs n=894 (1%) n (%) Untrea…”
Athyros, V. G., Elisaf, M., Alexandrides, T. K., Achimastos, A. D., Ganotakis, E. S., Bilianou, E., Karagiannis, A. I., Liberopoulos, E. N., Τζιόμαλος, Κ., Mikhailidis, D. P., et al. (2011) · Angiology · doi:10.1177/0003319711421341 · Cited by 30
“9 years) reported that the relationship between statin treatment and NOD is uncertain.(53) A more recent meta-analysis(12) included 13 statin trials and 91 140 patients.”
BackgroundStatin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial
Golomb, B. A., Dimsdale, J. E., Koslik, H. J., Evans, M. A., Lu, X., Rossi, S. S., Mills, P. J., White, H., & Criqui, M. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124451 · Cited by 28
Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment
Lang, W. R., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000258 · Cited by 29
Chung, C., Lin, M., Hsu, J., Hsiao, J., Chang, S., Pan, K., Lin, C., & Lin, Y. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.001 · Cited by 26
Engeda, J. C., Stackhouse, A., White, M., Rosamond, W. D., Lhachimi, S. K., Lund, J. L., Keyserling, T. C., & Avery, C. L. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.005 · Cited by 33
Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study
Olotu, B., Shepherd, M. D., Novak, S., Lawson, K. A., Wilson, J. P., Richards, K. M., & Rasu, R. S. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0176-1 · Cited by 26
Kumar, V., Sharma, P., Bairagya, H. R., Sharma, S. P., Singh, T. P., & Tiku, P. K. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.04.002 · Cited by 28
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
Pirillo, A., & Catapano, A. L. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000706 · Cited by 29
Tousoulis, D., Koniari, K., Antoniades, C. A., Miliou, A., Noutsou, M., Nikolopoulou, A., Παπαγεωργίου, Ν., Marinou, K., Stefanadi, E., & Stefanadis, C. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.09.007 · Cited by 25
Metadata
- Authors
- Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Cleveland Clinic (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Rajpathak, Swapnil N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-10-01
- Volume
- 32
- Issue
- 10
- Pages
- 1924-1929
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2752935
- OpenAlex
- W2121535401
- Cited by
- 439
- References
- 21
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 20 · 2023: 15 · 2022: 19 · 2021: 19 · 2020: 16 · 2019: 34 · 2018: 21 · 2017: 28 · 2016: 27 · 2015: 45 · 2014: 41 · 2013: 50 · 2012: 44
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (5P60DK2054, P60DK020541)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin therapy, type 2 diabetes, incident diabetes risk, WOSCOPS, Heart Protection Study, ASCOT trial, JUPITER trial, CORONA trial, cardiovascular risk
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Risk Factors, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

